These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19191685)

  • 1. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Pratley RE
    Expert Opin Pharmacother; 2009 Feb; 10(3):503-12. PubMed ID: 19191685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
    Ndefo UA; Okoli O; Erowele G
    Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI; Cabrera A; Charron D
    Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
    Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alogliptin: safety, efficacy, and clinical implications.
    Marino AB; Cole SW
    J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
    Fujii Y; Abe M; Higuchi T; Mizuno M; Suzuki H; Matsumoto S; Ito M; Maruyama N; Okada K; Soma M
    Expert Opin Pharmacother; 2013 Feb; 14(3):259-67. PubMed ID: 23289982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alogliptin: a review of its use in patients with type 2 diabetes mellitus.
    Keating GM
    Drugs; 2015 May; 75(7):777-96. PubMed ID: 25855222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
    Ji L; Li L; Kuang J; Yang T; Kim DJ; Kadir AA; Huang CN; Lee D
    Diabetes Obes Metab; 2017 May; 19(5):754-758. PubMed ID: 28075066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2010 Oct; 70(15):2051-72. PubMed ID: 20883057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 15. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.
    Ghatak SB; Patel DS; Shanker N; Srivstava A; Deshpande SS; Panchal SJ
    Curr Diabetes Rev; 2010 Nov; 6(6):410-21. PubMed ID: 20879969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
    Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
    J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
    White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
    Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M; Drincic A; Andukuri R
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.
    Kaku K; Katou M; Igeta M; Ohira T; Sano H
    Diabetes Obes Metab; 2015 Dec; 17(12):1198-201. PubMed ID: 26277887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.